Fingerprint
Dive into the research topics of 'Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma
Harry Yoon, Lilit Karapetyan, Anita Choudhary, Ramla Kosozi, Gurvinder Singh Bali, Ali H. Zaidi, Ajlan Atasoy, Arlene A. Forastiere, Michael K. Gibson
Research output: Contribution to journal › Article › peer-review
3
Scopus
citations